These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29441502)

  • 41. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?
    McDonald H; Charles C; Elit L; Gafni A
    Pharmacoeconomics; 2015 Mar; 33(3):235-41. PubMed ID: 25424496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
    Hernandez L; O'Donnell M; Postma M
    Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Common methodological flaws in economic evaluations.
    Drummond M; Sculpher M
    Med Care; 2005 Jul; 43(7 Suppl):5-14. PubMed ID: 16056003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cervical spondylotic myelopathy: methodological approaches to evaluate the literature and establish best evidence.
    Skelly AC; Hashimoto RE; Norvell DC; Dettori JR; Fischer DJ; Wilson JR; Tetreault LA; Fehlings MG
    Spine (Phila Pa 1976); 2013 Oct; 38(22 Suppl 1):S9-18. PubMed ID: 24026148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
    Ghabri S; Hamers FF; Josselin JM
    Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Housing improvements for health and associated socio-economic outcomes.
    Thomson H; Thomas S; Sellstrom E; Petticrew M
    Cochrane Database Syst Rev; 2013 Feb; (2):CD008657. PubMed ID: 23450585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
    Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
    Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
    Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
    Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews.
    Gibson W; Wand BM; Meads C; Catley MJ; O'Connell NE
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011890. PubMed ID: 30941745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.
    Ismail Z; Peacock SJ; Kovacic L; Hoch JS
    Int J Technol Assess Health Care; 2017 Jan; 33(4):481-486. PubMed ID: 28871898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between a reviewer's recommendation and editorial decision of manuscripts submitted for publication in obstetrics.
    Vintzileos AM; Ananth CV; Odibo AO; Chauhan SP; Smulian JC; Oyelese Y
    Am J Obstet Gynecol; 2014 Dec; 211(6):703.e1-5. PubMed ID: 24983685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No. 385-Indications for Pelvic Examination.
    Evans D; Goldstein S; Loewy A; Altman AD
    J Obstet Gynaecol Can; 2019 Aug; 41(8):1221-1234. PubMed ID: 31331610
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.